Sorafenib targets the Raf/mitogen activated protein kinase, VEGF and PDGF pathways and prolongs survival patients in advanced hepatocellular carcinoma (HCC). Everolimus inhibits the mammalian target of rapamycin, a kinase overactive in HCC. To investigate whether the antitumor effects of these agents are additive, we compared a combined and sequential treatment regimen of everolimus and sorafenib with monotherapy. After hepatic implantation of Morris Hepatoma cells, rats were randomly allocated to everolimus (5mg/kg, 2x/week), sorafenib (7.5mg/kg/day), combined everolimus and sorafenib, sequential sorafenib (2 weeks) then everolimus (3 weeks), or control groups. Magnetic resonance imaging quantified tumor volumes.
INTRODUCTION
Sorafenib is the only drug for which randomized control trials have shown an improved survival in advanced hepatocellular carcinoma (HCC) [1] , [2] , and is the only systemic targeted therapy approved for clinical use in many countries. Sorafenib inhibits the kinase activity of Raf, an enzyme operative within the mitogen-activated protein kinase (MAPK) signaling pathway and inhibits the vascular endothelial growth factor receptors (VEGFR) and platelet-derived growth factor receptor-PDGFIn many cases of HCC, Ras kinase is over-expressed or mutated and the Raf/MAPK pathway is activated [3] . As a result of the inhibition of these target molecules, sorafenib decreases tumor microvessel density and exerts an anti-proliferative effect on tumor cells [4] . Despite these actions, sorafenib only extends the life expectancy of patients with HCC by a few months, suggesting that other signaling pathways remain active.
Additional pathways implicated in tumorigenesis include those signaling through PI(3)K/Akt -catenin, insulin-like growth factor, hepatocyte growth factor/c-MET and growth factor-regulated angiogenic signaling (VEGF, PDGF, EGF) [5] . In this study we focused on the PI(3)K/Akt/mTOR signaling cascade. The mammalian target of rapamycin (mTOR), which is the downstream target of the serine/threonine kinase Akt, increases protein synthesis and cell proliferation in response to growth factors.
Pharmacological inhibition of mTOR by rapamycin and its analogues arrests the cell cycle by abrogating the PI(3)K/Akt-mediated proliferative signals. Moreover, mTOR inhibitors reduce the expression of VEGF, which is associated with tumor angiogenesis [6] . We reported previously that inhibition of mTOR significantly slows tumor growth, impairs the tumor angiogenesis that occurs by sprouting, and improves survival in an experimental HCC model [6] . Everolimus, a rapamycin analogue, is the only mTOR inhibitor currently under shown synergistic inhibition of HCC xenografts [7] , important information is lacking with respect to the mechanisms of this synergism and the specific effects of the drug combination on angiogenic processes. Additional uncertainties relate to the most effective means of administering the drug combination and whether patients who have been unresponsive or intolerant to sorafenib could subsequently benefit from an mTOR inhibitor.
We asked whether the anti-proliferative and anti-angiogenic properties of everolimus and sorafenib in liver tumors are additive when administered in combination, whether their concomitant use improves survival, and whether administration of everolimus sequentially after sorafenib is beneficial. We chose an orthotopic syngeneic rat model of HCC and examined the effects of everolimus and sorafenib on tumor vasculature and different cell types. Our results provide a rationale for combining everolimus with sorafenib in HCC. 
MATERIAL AND METHODS

Animals and surgical procedures
Animal experiments were approved by the Local Animal Use Committee. The livers of male ACI rats (Harlan, Indianapolis, IN), 10-12 weeks old, were surgically implanted with tumors derived from Morris Hepatoma MH-3924A cells as previously described [6] , [8] .
Animal treatment protocol
On day 6 post tumor implantation, the rats were randomized to a group receiving either everolimus (5mg/kg 2x/week; Novartis, Basel, Switzerland; structural formula in Supplementary Figure 1A) , sorafenib (7.5mg/kg/day; Bayer HealthCare Pharmaceuticals Montville, NJ; structural formula in Supplementary Figure 1B) , the combination of everolimus and sorafenib, or the successive treatment of sorafenib for 2 weeks followed by everolimus for 3 weeks, or to a control group. Drugs and vehicle were administered by gavage. Rats were euthanized on day 42 after tumor implantation. In a second series of experiments designed to measure survival, animals were treated until the appearance of signs of wasting or suffering that indicated distress (deterioration of the general state of the animals, loss of weight greater than 20%, severe piloerection, harderian gland secretion, abnormal posture and behaviour), at which point they were euthanized. The investigators were blinded to treatment allocation.
MR Imaging
Liver MR imaging with a commercial 3.0 Tesla system (TIM TRIO, Siemens, Erlangen, Germany) of tumors was first performed on day 11 after tumor implantation and weekly thereafter. All animals received food and water ad libitum. Animals were anesthetized and placed prone and head first in an eight-channel-wrist coil. After visualization of the liver, a · r 1 · r 2 · r 3 (with r 1 , r 2 and r 3 representing perpendicular radii of the lesion).
Immunohistochemistry
Tumor necrosis was assessed by staining tumor sections with Giemsa and by quantifying the necrotic area using the software Metamorph. Tumoral apoptosis was measured in paraffinembedded sections by cleaved-caspase 3 immunostaining (Cell Signaling, Beverly, MA).
Tumoral hypoxia was measured in paraffin-embedded sections by HIFng Relative fold increases or decreases were calculated using the formula 2 -Ct . All reactions were performed in triplicate.
Real time quantitative PCR
Vascular casting
As previously described [9] , the liver vasculature was perfused with a freshly prepared solution of Mercox® (Vilene Company, Japan) containing 0.1 ml accelerator per 5 ml resin.
One hour after perfusion, the tumors were excised and macerated in 15% potassium hydroxide. After 3 to 4 weeks, the casts were washed and dehydrated in ethanol and desiccated under vacuum. Samples were layered with gold to a thickness of 10 nm and examined in a Philips XL 30 FEG scanning electron microscope. 
Cells and culture conditions
Rat aortic ring assay
Aortic rings were prepared as previously described [6] . Everolimus and/or sorafenib were added 24h after preparation and rings were incubated for 5 days. For sequential drug treatment, rings were incubated with sorafenib for two days, the medium was changed and everolimus was added. At day 5, the rings were fixed and stained according to a Diff-Quick solution II protocol (Diff-Quick Stain Set; Baxter-Dade AG, Switzerland). Vascular outgrowth was quantified by counting the sprouts.
Tube formation assay
HHSEC (4x10 4 ) were incubated in 24-well plates coated with Matrigel in the presence or absence of everolimus and/or sorafenib. After 72 hours, the area covered with vascular tubes was quantified using the Metamorph software (Molecular Devices, Sunnyvale, CA).
Experiments were performed 3 times in duplicate.
Immunoblot analysis
Liver tissue was homogenized in RIPA buffer (150 mM NaCl, 1% NP-40, 0.5% Nadeoxycholate, 0.1% SDS and 50 mM Tris-HCl pH 7.4) containing protease and phosphatase inhibitors (Roche, Rotkreuz, Switzerland). Protein concentration was assayed according to Lowry [10] . Equal amount of proteins were separated by SDS-PAGE and transferred to nitrocellulose membranes, blocked for 1 hour with 5% nonfat milk, then incubated overnight at 4°C with cleaved-Caspase 3, phospho-Erk1/2, phospho-4E-BP1, phospho-Elk1 and phospho-Akt (Ser473) antibodies (Cell Signaling, Beverly, MA). After washing, the membranes were incubated with peroxidase-conjugated secondary antibody (Pierce, Lausanne, Switzerland) and signals were revealed using an enhanced chemiluminescence detection system (Perkin Elmer, Schwerzenbach, Switzerland) and a Fujifilm LAS.100 CCD camera coupled to a computer using the software AIDA 2.1 (Raytest, Urdorf, Switzerland).
Membranes were stripped and reincubated with antibodies against total Erk1/2, 4E-BP1, Elk1
and Akt (Cell Signaling). Membranes were stripped again before incubation with anti--actin antibody (Sigma-Aldrich Chemie GmbH, Munich, Germany) and protein was normalized for actin expression.
Statistical analysis
Data points represent the mean values ± SD. Data were compared by applying the The addition of everolimus lowered the minimal effective concentration of sorafenib to 5
( Figure 3B ).
The effect of sorafenib and everolimus on angiogenesis in vitro was measured in two ways.
In the aortic ring assay, everolimus 200 nM and sorafenib 100 nM alone significantly decreased sprouting from aortic rings by 60% ( Figure 4A ). The combination of drugs, either in a concomitant or sequential regimen, decreased sprouting even further ( Figure 4A ). In fact, vessel sprouting was most inhibited by the sequential sorafenib-everolimus treatment protocol. The tube formation assay measures the ability of endothelial cells to form a linear structure and in contrast to the ring aortic assay, operates without the confounding influences of pericytes and fibroblasts. Endothelial tube formation was significantly impaired by everolimus both in monotherapy and in combination ( Figure 4B ). Sorafenib had no effect in this assay. 
Effect of combined everolimus
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DISCUSSION
We previously reported that inhibition of the mTOR pathway, which is activated in many cases of HCC [11] , [12] , [13] , decreases VEGF levels, impairs tumor angiogenesis, and results in smaller tumors and longer survival in a rat MH-3924A model of HCC [6] . We now show the benefits of combining an mTOR inhibitor with sorafenib, an inhibitor of B-Raf and Raf-1 kinases, as well as VEGF and PDGF receptor Our findings show that combined everolimus and sorafenib is a more potent anti-tumor regimen than either agent alone, exerts a stronger anti-angiogenic effect than either agent alone and improves survival in this HCC model. Everolimus also retains its antitumoral potency in vivo when administered sequentially after sorafenib, a finding that carries important clinical implications. Our positive results contrast with those of Newell et al., who found no difference in tumor growth with this combination [14] . This disparity is perhaps explained by our propitious choice of an orthotopic syngeneic model, which is a closer representation of HCC than the xenograft model chosen by previous investigators [14] , [7] , [15] HCC is a hypervascular tumor, relying on angiogenesis for growth [16] . Focal hypoxia is a potent angiogenic stimulus and both everolimus and sorafenib treatment regimens exerted their antitumoral effects within a local environment that was subject to such stimuli, as shown by the increased expression of HIF-1 ure 2D). The upregulation of Vegf-a mRNA in the tumor by sorafenib, an effect also reported with other receptor tyrosine kinase inhibitors such as vatalanib [17] and sunitinib [18] , can be attributed to a feedback response to the suppressed VEGF receptor signaling [19] . Despite this, hypoxia-driven neovascularisation was not seen in the treated liver tumors. Rather, everolimus and sorafenib impaired angiogenesis and altered the structure of the tumor vascular architecture ( Figure   6A ). In keeping with our previous findings, where inhibition of mTOR with sirolimus effected a switch in tumor angiogenesis from sprouting to intussusception [6] , the combination of everolimus/sorafenib promoted an increase in the number of vascular pillars but these pillars remained small, which suggests an inability to fuse, and consequently an impairment of the process of intussusception as a means of tumor vascularization. We ascribe the superior ability of the everolimus and sorafenib combination to slow tumor growth to this impaired tumor angiogenesis and vascularization.
The innate resistance of the MH-3924A cells to the anti-proliferative actions of mTOR inhibition and the low sensitivity to Raf/ERK blockade in vitro ( Figure 3B ) did not preclude a response to everolimus and sorafenib when these cells were implanted as solid tumors in vivo.
Other investigators have reported similar anti-tumoral responses when insensitive cell lines
were seeded in vivo [20] , [21] . The everolimus mediated decrease in proliferation and migration of endothelial cells in vitro and impairment of vessel sprouting point to antiangiogenesis as the means by which the resistant tumors became sensitized to mTOR inhibition in vivo. Lane et al. postulated that the anti-antiogenic effects of everolimus were due to the combination of a reduced VEGF production in tumor cells and direct action on mTOR signalling in non-tumor pericytes and endothelial cells [20] . We have previously reported that another mTOR inhibitor, sirolimus, did decrease VEGF-a in MH-3924A derived tumors under different experimental circumstances [6] . A similar reduction was not detected with everolimus, although the sorafenib-induced increase in VEGF-a mRNA tended to be less acute in the presence of everolimus ( Figure 5A ). Our findings appear more consistent with inhibition of mTOR signalling in endothelial cells ( Figures 3A, 4) . The basis for the resistance of MH-3924A cells to everolimus has not been investigated. The presence of an oncogenic mutation in PI-3-been linked to mTOR inhibitor sensitivity [22] . mTOR inhibitor insensitivity, as has overexpression of the myc oncogene [23] . The MH-
3924A cells likely overexpress K-Ras since gene amplification was detected in several Morris
Hepatoma cell lines [24] but a more extensive genotyping is required to fully explain the response to mTOR signalling inhibition. Genotyping may also explain the basis for the low sensitivity of MH-3924A cells to sorafenib ( Figure 3B ). Tumor cell lines containing an activating receptor tyrosine kinase mutation are more sensitive to sorafenib whereas cell lines in which multiple signalling pathways drive growth are less sensitive [25] . The growthinhibitory response of MH-3924A tumors to sorafenib alone was poor ( Figure 1B Figures 2B and 2C) , an effect likely explained by the reduced phosphorylation of the initiation factor eIF4E and downregulation of the antiapoptotic protein Mcl-1 [25] . Sorafenib blocks the VEGFR-2 receptor, an effect which could be linked to anti-angiogenesis through decreased endothelial cell survival. Endothelial cell survival is assured through anti-apoptotic signalling, which normally occurs through Akt/PBK via the PI3 kinase-dependent pathway and up-regulation of anti-apoptotic protein signalling [26] . In support of this, sorafenib did decrease the phosphorylation of AKT in endothelial cells in vitro (data not shown).
The molecular mechanism by which everolimus and sorafenib combine to exert effective antitumor activity in MH-3924A derived tumors has been partly elucidated in our studies. The combination therapy did increase the pAkt Ser473/Akt ratio in our tumor model ( Figures 5C   and S3) , which was likely due to the mTOR complex 2-dependent phosphorylation of Akt in tumoral cells. However, a higher AKT phosphorylation is not necessarily incompatible with a reduction in tumor growth [27] , [28] . In fact, induction of p-AKT secondary to mTOR inhibition was shown to be independent of the anti-proliferation cellular response to everolimus and modulation of AKT phosphorylation alone does not predict effects on downstream signalling [28] . Therefore, the anti-tumoral benefit of the combined treatment in our tumor model depends on pathways unrelated to the tumoral AKT signalling. The combination of everolimus and sorafenib also annulled the hypophosphorylation of 4E-BP1 elicited by everolimus alone in tumor tissue ( Figure S3) . However, the phosphorylation of the ribosomal protein S6 was completely inhibited in tumors treated with both everolimus and the combination (data not shown), which confirms the pharmacological inhibition of the mTOR complex 1. Since the MH-3924A cell line is insensitive to everolimus, and inhibition of S6 kinase and hypophosphorylated 4E-BP1 has been demonstrated in cell lines that were both sensitive and resistant to everolimus [28] , we conclude that the ratio p4E-BP1/4E-BP1 in total tumoral tissue is not an adequate pharmacodynamic marker for the anti-tumoral effects of combined everolimus and sorafenib. The addition of everolimus to sorafenib annulled the effect of sorafenib on the phosphorylation of Erk1/2 and downstream pElk1 ( Figure S3 ). One explanation is that Erk1/2 may be phosphorylated by a kinase other than Raf. A second explanation is that the phosphorylation of Erk1/2 could be regulated by cross talk between PI3K/Akt and MAPK signaling due to a feedback loop affecting the S6K-PI3K-Ras pathway [29] . The increase in ERK phosphorylation observed after the combined everolimus and sorafenib is not incompatible with better anti-tumoral properties because of the likelihood that MEK/ERK-independent mechanisms are responsible for the reduced growth of MH-3924A tumors. We argue that everolimus and sorafenib together reduced tumor growth in vivo more effectively than monotherapies primarily because of the combined effects of inhibition of mTOR signalling in endothelial cells and perhaps in non-tumor pericytes [20] , and of sorafenib-induced tumor cell apoptosis and reduced anti-apoptotic signalling in endothelial cells and perhaps in other supportive cells of the vasculature. 
A comparison of the peripheral tumor regions revealed distinct histological differences between treatment and control groups. The tumor front, which was linear and often encapsulated in the control group, appeared irregular and invasive after treatment, and prominently intermingled with the surrounding tissue to produce isolated islands of tumor tissue. These features were particularly evident in the combination group. Although this suggested a more invasive tumor phenotype [30] , no distant metastases were detected in any of the animals at the time of harvesting. We speculate that the treated tumors differed from the untreated tumors because the treated tumors have evolved in an anti-angiogenic environment and must rely on the blood supply at the peripheral edges to support growth.
Whether the differences in staining pattern of E-cadherin at the tumor interface influence the pattern of invasiveness observed is not known at this point [31] .
Despite a superior reduction in tumor growth, the effect of the everolimus-sorafenib combination on the median survival remained modest in comparison to the other treatment options. Our survival study was designed with conditions wherein rats were euthanized when explicit endpoint criteria linked to distress had been reached. Because the endpoint criteria would have precipitated termination of the study for the distressed animals, the effect of the combination everolimus-sorafenib on the median survival was modest. We would expect a larger clinical effect on the median natural survival of patients. [32] . This rebound effect could be provoked partly by an increased concentration of growth factors such as VEGF as we report here, which may fuel tumor growth if left unopposed. Our results offer reassurance that patients can still benefit from an alternative systemic targeted therapy after sorafenib and that everolimus can still exert its antiangiogenic effects. However, the extent of the clinical improvement that can be offered to patients remains to be verified. One must also carefully consider whether the combination of an inhibitor of mTOR and sorafenib will be tolerated by patients with liver cirrhosis.
In conclusion, our results present mechanistic insights into the treatment of HCC with everolimus either in combination with sorafenib or in subsequent treatment and provide the experimental basis for testing this combination in clinical trials. for sorafenib treatment and N=5 for combination treatment). 
